Financials Xlife Sciences AG BOERSE MUENCHEN
Equities
XLS
CH0461929603
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.8 EUR | -0.48% | -7.52% | -3.69% |
04-23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
02-29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 |
---|---|---|---|
Capitalization 1 | 156.9 | 279 | 201.3 |
Enterprise Value (EV) 1 | 216.9 | 335.2 | 266.5 |
P/E ratio | 14.9 x | 24 x | -53.5 x |
Yield | - | - | - |
Capitalization / Revenue | 153 x | 282 x | 252 x |
EV / Revenue | 211 x | 339 x | 333 x |
EV / EBITDA | -43.7 x | -78.4 x | -66.6 x |
EV / FCF | -46.3 x | - | -53.3 x |
FCF Yield | -2.16% | - | -1.88% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 5,284 | 5,590 | 5,703 |
Reference price 2 | 29.70 | 49.90 | 35.30 |
Announcement Date | 20/04/23 | 29/02/24 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales 1 | 0.3968 | 0.8061 | 1.028 | 0.9884 | 0.8 |
EBITDA 1 | -2.964 | - | -4.961 | -4.278 | -4 |
EBIT 1 | -3.025 | - | -20.98 | -20.31 | -4.19 |
Operating Margin | -762.31% | - | -2,041.2% | -2,054.54% | -523.75% |
Earnings before Tax (EBT) 1 | 21.26 | - | 4.039 | 4.534 | -5 |
Net income 1 | 21.62 | 53.42 | 14.31 | 14.88 | -4 |
Net margin | 5,449.53% | 6,627.03% | 1,392.26% | 1,505.33% | -500% |
EPS 2 | - | - | 2.000 | 2.080 | -0.6600 |
Free Cash Flow 1 | -0.4577 | - | -4.688 | - | -5 |
FCF margin | -115.35% | - | -456.01% | - | -625% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 31/03/21 | 29/04/22 | 20/04/23 | 29/02/24 | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net Debt 1 | 50.8 | - | 60 | 56.2 | 65.2 |
Net Cash position 1 | - | - | - | - | - |
Leverage (Debt/EBITDA) | -17.15 x | - | -12.1 x | -13.14 x | -16.3 x |
Free Cash Flow 1 | -0.46 | - | -4.69 | - | -5 |
ROE (net income / shareholders' equity) | 19% | - | - | - | - |
ROA (Net income/ Total Assets) | 12.7% | - | - | - | - |
Assets 1 | 169.9 | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | - | 0.08 | - | 1 |
Capex / Sales | - | - | 7.8% | - | 125% |
Announcement Date | 31/03/21 | 29/04/22 | 20/04/23 | 29/02/24 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- XLS Stock
- XLS Stock
- Financials Xlife Sciences AG